Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Recruiting now

Conditions studied: Hepatic Insufficiency, Cirrhosis, Liver

In brief

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Key facts

Study ID

NCT07343037

Run by

University Hospital, Strasbourg, France

People needed

100

Starts

2025-08-29

Expected to finish

2026-08-29

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient (≥18 years old)
• Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
• At least 3 biological signs of HLH:
• ferritin > 2000 ng/mL
• triglycerides > 1.5 g/L
• at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL).

You may not qualify if…

• Refusal to participate in the study

Where it is running

• Médecine intensive - Réanimation - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.